Speaker(s): 

Kylie Barnes, Staff Member, UMKC School of Pharmacy - has reported the following disclosures: Wolters Kluwer [Consultant/Advisor], Inovio Pharmaceuticals [Stockholder], and American College of Clinical Pharmacy [Speakers Bureau].

Moderator(s): 

Daniel Longyhore, PharmD, Ed.D., BCACP, Staff Member, Geisinger - has nothing to disclose.   

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• discuss potential maternal and fetal complications associated with uncontrolled diabetes during pregnancy.
• summarize the various screening approaches used to diagnose gestational diabetes during pregnancy.
• evaluate a treatment plan for a patient with diabetes during pregnancy.
• develop an intrapartum and postpartum treatment plan for a patient with diabetes during pregnancy.
• create a long-term monitoring plan for a patient with a history of gestational diabetes during pregnancy.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, Ed.D., BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH; Lisabeth Karetsky, CPhT and Nichole Varela Gonzalez have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose.

Andrea Dimattia, EdD, and Dan Dometita, DO, FACP have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.